Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2.

Genocea is now running a Phase II trial to determine the best dose of the vaccine. “We have $100 million in the bank and we have over a year’s worth of runway,” he said at the time, adding that the company is in discussions on further funding options. While HerpV will be the first-in-class therapeutic vaccine for genital herpes, GlobalData anticipates a relatively low initial uptake based on available efficacy data, which are not encouraging enough to guarantee rapid adoption. According to the Centers for Disease Control, genital herpes affects more than 60 million Americans—or 1 in 6 people between ages 14 and 49—with an additional 1.5 million new cases each year.1 This disease normally results in 6 outbreaks per year, but in severe cases more episodes may result.2 The psychosocial consequences of genital herpes are quite significant, as 57 percent of those infected indicated that herpes had interfered with their sexual relationships, 50 percent felt it was difficult to live with genital herpes, and 37 percent felt that herpes had ruined their lives.3 Additionally, ongoing research indicates an increasing resistance to currently available genital herpes treatments. According to the Centers for Disease Control, genital herpes affects more than 60 million Americans—or 1 in 6 people between ages 14 and 49—with an additional 1.5 million new cases each year.1 This disease often results in recurrent painful sores in the genital area.2 The emotional consequences of genital herpes are quite significant, as 82 percent of people in the study reported depression, 75 percent experienced fear of rejection, 69 percent cited feelings of isolation and 55 percent reported fear of discovery — all due to infection.3 Current therapies involve taking a daily medication that only partly suppresses the virus. This is because the culture of CMV doesn’t exist.


Dr. Key topics covered include strategic competitor assessment, market characterization, unmet needs, research and development strategies, and clinical trial design. Overall, the early-stage clinical trial results for both HerpV and GEN-003 have been positive. They will receive a booster injection of study drug or placebo according to their orginal randomization assignment. These adverse events are short-lived and include flu-like symptoms and injection-site reactions. According to the Centers for Disease Control, genital herpes affects more than 60 million Americans-or 1 in 6 people between ages 14 and 49-with an additional 1.5 million new cases each year.1 This disease often results in recurrent painful sores in the genital area.2 The emotional consequences of genital herpes are quite significant, as 82 percent of people in the study reported depression, 75 percent experienced fear of rejection, 69 percent cited feelings of isolation and 55 percent reported fear of discovery — all due to infection.3 Current therapies involve taking a daily medication that only partly suppresses the virus.

The majority of subjects in the study have received a booster injection of HerpV that was given six months after the first vaccination followed by determination of genital viral shedding for an additional 45-day period. has been positive based on 25 corporate insider transactions. Success for either vaccine candidate could end the need for daily antiviral doses. believed to have HSV-1 (often in the form of oral herpes that causes cold sores). A, An infected P19 neuron and A1, A higher magnification of a dendrite revealing two green virions attached. “There are currently 16 QS-21 containing vaccines in clinical development and we look forward to significant news flow from our partners with pivotal data readouts expected from at least four key clinical programs that incorporate QS-21,” said Garo H.

A booster injection will be given at six months after treatment to evaluate the durability of treatment effect. In January, Incyte Corp inked a deal with Agenus to develop new therapeutics targeting immune system checkpoints. A good way to stay ahead of the curve with regards to your intimate health can be to make cure hsv 1 2015 sure that all of the relevant assessments are taken. QS-21 Stimulon was widely studied in clinical development and tens of thousands of patients received vaccines containing the adjuvant, Pharmabiz.com reports. More than 8,300 women volunteered to receive three shots of a HSV-2 vaccine over six months in a clinical trial sponsored by Glaxo. CPM combination with a high cure rate for a difficult cancer, the sky is the limit.